TICKERNOMICS Sign up
Last Update: 2023-12-23 06:00:48
IGM Biosciences Inc. ( IGMS ) https://igmbio.com
8.63USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
23.45%
-49.25%
IGMS
SPY
30.72%
-89.93%
IGMS
SPY
112.82%
IGMS
0.00%
SPY
201.04%
IGMS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
297.81
126.80
0.37
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-1.27
160.89
1.17
-8.02
0.00
-0.51
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-13115.91
100.00
-13327.82
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
3.86
-149.06
-71.73
0.00
Other Earnings and Cash Flow Stats:
IGM Biosciences Inc. ( IGMS ) Net Income TTM ($MM) is -225.06
IGM Biosciences Inc. ( IGMS ) Operating Income TTM ($MM) is -246.91
IGM Biosciences Inc. ( IGMS ) Owners' Earnings Annual ($MM) is 0.00
IGM Biosciences Inc. ( IGMS ) Current Price to Owners' Earnings ratio is 0.00
IGM Biosciences Inc. ( IGMS ) EBITDA TTM ($MM) is -239.67
IGM Biosciences Inc. ( IGMS ) EBITDA Margin is -13327.82%
Capital Allocation:
IGM Biosciences Inc. ( IGMS ) has paid 0.00 dividends per share and bought back -1.088248 million shares in the past 12 months
IGM Biosciences Inc. ( IGMS ) has increased its debt by 13.11 million USD in the last 12 months
Capital Structure:
IGM Biosciences Inc. ( IGMS ) Interest-bearing Debt ($MM) as of last quarter is 41
IGM Biosciences Inc. ( IGMS ) Annual Working Capital Investments ($MM) are 221
IGM Biosciences Inc. ( IGMS ) Book Value ($MM) as of last quarter is 253
IGM Biosciences Inc. ( IGMS ) Debt/Capital as of last quarter is 16%
Other Balance Sheet Stats:
IGM Biosciences Inc. ( IGMS ) has 174 million in cash on hand as of last quarter
IGM Biosciences Inc. ( IGMS ) has 42 million of liabilities due within 12 months, and long term debt 0 as of last quarter
IGM Biosciences Inc. ( IGMS ) has 45 common shares outstanding as of last quarter
IGM Biosciences Inc. ( IGMS ) has 0 million USD of preferred stock value
Academic Scores:
IGM Biosciences Inc. ( IGMS ) Altman Z-Score is -2.30 as of last quarter
IGM Biosciences Inc. ( IGMS ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
IGM Biosciences Inc. ( IGMS ) largest shareholder is Geode Capital Management, LLC owning 220417 shares at 1.90 ($MM) value
Bros. Advisors Lp Baker(an insider) Bought 288007 shares of IGM Biosciences Inc. ( IGMS ) for the amount of $1886445.85 on 2023-12-15
36.80% of IGM Biosciences Inc. ( IGMS ) is held by insiders, and 57.18% is held by institutions
IGM Biosciences Inc. ( IGMS ) went public on 2019-09-18
Other IGM Biosciences Inc. ( IGMS ) financial metrics:
FCF:-31.23
Unlevered Free Cash Flow:0.00
EPS:-5.71
Operating Margin:-13115.91
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-97.67
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About IGM Biosciences Inc. ( IGMS ) :
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's product candidate, including imvotamab (IGM-2323), an IgM-based CD20 x CD3 bispecific antibody T cell engager that is in Phase 2 clinical trials for the treatment of B cell non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1a/1b clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody that is in Phase 1 clinical trials for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.